Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer

Increased odds of LV hypertrophy, high relative wall thickness, LV diastolic dysfunction, high LV filling pressure

Higher increase in rates over time seen for Black and Asian patients versus White patients and for Medicaid, Medicare patients

Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm

Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator

Two-year cumulative rate of invasive ipsilateral breast cancer 5.9 and 4.2 percent for guideline-concordant care, active monitoring

Imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, but not in overall population

By Dennis Thompson HealthDay ReporterTHURSDAY, Dec. 12, 2024 (HealthDay News) — In news that suggests the U.S. opioid epidemic may be easing, drug overdose deaths fell 17% between July 2023 and July 2024.Per new data released Wednesday by the U.S. Centers for Disease Control and Prevention, about 94,000 people died …

Significant increase seen in incidence rates at presentation for women overall, and for those aged 20 to 39, 40 to 74, and 75 years or older

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients